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Abstract
Background: Successful neovascularization requires that sprouting endothelial cells (ECs) integrate to form new vascular
networks. However, architecturally defective, poorly integrated vessels with blind ends are typical of pathological
angiogenesis induced by vascular endothelial growth factor-A (VEGF), thereby limiting the utility of VEGF for therapeutic
angiogenesis and aggravating ischemia-related pathologies. Here we investigated the possibility that over-exuberant
calpain activity is responsible for aberrant VEGF neovessel architecture and integration. Calpains are a family of intracellular
calcium-dependent, non-lysosomal cysteine proteases that regulate cellular functions through proteolysis of numerous
substrates.
Methodology/Principal Findings: In a mouse skin model of VEGF-driven angiogenesis, retroviral transduction with
dominant-negative (DN) calpain-I promoted neovessel integration and lumen formation, reduced blind ends, and improved
vascular perfusion. Moderate doses of calpain inhibitor-I improved VEGF-driven angiogenesis similarly to DN calpain-I.
Conversely, retroviral transduction with wild-type (WT) calpain-I abolished neovessel integration and lumen formation. In
vitro, moderate suppression of calpain activity with DN calpain-I or calpain inhibitor-I increased the microtubule-stabilizing
protein tau in endothelial cells (ECs), increased the average length of microtubules, increased actin cable length, and
increased the interconnectivity of vascular cords. Conversely, WT calpain-I diminished tau, collapsed microtubules, disrupted
actin cables, and inhibited integration of cord networks. Consistent with the critical importance of microtubules for vascular
network integration, the microtubule-stabilizing agent taxol supported vascular cord integration whereas microtubule
dissolution with nocodazole collapsed cord networks.
Conclusions/Significance: These findings implicate VEGF-induction of calpain activity and impairment of cytoskeletal
dynamics in the failure of VEGF-induced neovessels to form and integrate properly. Accordingly, calpain represents an
important target for rectifying key vascular defects associated with pathological angiogenesis and for improving
therapeutic angiogenesis with VEGF.
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Introduction
Vascular endothelial growth factor-A (VEGF) is essential for
embryonic vasculogenesis and for angiogenesis in a variety of
important pathologies including ischemia and wound repair,
proliferative retinopathies, psoriasis, rheumatoid arthritis, and
cancers [1]. Paradoxically, VEGF induces a highly abnormal
vasculature in pathological settings. Typical vascular abnormalities
include vessel tortuosity, abnormal vessel spacing and branching,
vessel leakiness, and failed integration of vascular networks
resulting in numerous blind ends (reviewed in [2,3]). These
architectural defects result in poor blood vessel function, especially
poor blood flow. Vascular abnormalities may be due to
comparatively high VEGF expression in pathological settings [4]
and also may result from an imbalance between VEGF and other
important factors [2], including the vascular cytokine angiopoie-
tin-1 [5]. Regardless, cellular mechanisms responsible for
abnormal neovascularization in pathological settings have been
largely unexplored.
In searching for mechanistic explanations for the architectural
defects associated with abnormal angiogenesis, we became
interested in a possible connection between failed integration of
neovascular networks, VEGF, and calpain activity. Calpains are
intracellular, calcium-dependent thiol proteases (reviewed in [6]).
Upon activation, these widely expressed enzymes cleave a broad
spectrum of functionally important intracellular protein targets [6]
that regulate cytoskeletal organization [7], cell adhesion and
spreading [8,9,10], and cell migration [10,11,12]. Moreover,
VEGF has been shown previously to induce calpain activity in
endothelial cells (ECs) [13,14]. Therefore, we directly examined
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VEGF-induced neovascular networks in vivo with both genetic and
pharmacologic approaches. We also employed in vitro models of
capillary morphogenesis to explore, at the cellular level, mecha-
nisms by which calpain activity controls the assembly and
organization of ECs into new blood vessels. Our findings directly
implicate VEGF-induction of calpain activity in the failed inter-
connectivity of neovascular networks and illustrate that appropri-
ate inhibition of calpain substantially improves neovessel integra-
tion and lumen formation.
Results
A Dominant-negative Mutant of Calpain-I Improves VEGF
Neovessel Integration and Lumen Formation In Vivo
To investigate a possible relationship between calpain activity
and abnormal neovascular architecture, we employed an estab-
lished mouse model of VEGF-driven angiogenesis [15,16]. This
model utilizes immortalized, transfected cells engineered for
continuous expression and secretion of VEGF165 under the
direction of a constitutively active cytomegalovirus immediate-
early gene (CMV) promoter. To provoke angiogenesis, the VEGF-
expressing cells are mixed with basement membrane Matrigel, and
the mixture is injected into the sub-dermal space. Robust
angiogenesis in the overlying dermis is typically evident by four
days, and the neovasculature routinely exhibits all of the hallmarks
of pathological angiogenesis (e.g., vessel tortuosity, abnormal vessel
spacing and branching, vessel leakiness, and failed integration of
vascular networks resulting in numerous blind ends). In addition to
the VEGF-expressing cells, we included equal numbers of
retroviral packaging cells in the Matrigel for continuous delivery
of engineered retroviruses. The different retroviral packaging cells
expressed retrovirus encoding either a validated dominant-
negative (DN) mutant of calpain-I [8], wild type (WT) calpain-I
[8], or no insert (empty vector). This retrovirus-based model of
VEGF-driven angiogenesis offers the advantage of high retroviral
transduction efficiency that is favored in proliferating cells, and
ECs are actively dividing in response to continuous VEGF-
stimulation [15,16]. Moreover, the inclusion of packaging cells
provides a constant source of freshly produced retrovirus
throughout the experimental interval. Previously, the efficacy of
this model has been validated with packaging cells expressing
retrovirus encoding GFP [16], RhoA mutants [15], and
transcription factor Nur77 [17].
Animals were harvested on day 8 following induction of
angiogenesis, at which time neovascularization of the over-lying
dermis was extensive. As shown with CD31-staining of paraffin
sections (Fig. 1, top panels), ECs in the VEGF + DN calpain-I
specimens were well organized into blood vessels with clearly
distinguished lumens, whereas ECs in the VEGF + WT calpain-I
group were very poorly organized and lumens were nearly absent.
ECs in VEGF + empty vector specimens exhibited intermediate
lumen formation (Fig. 1, top panels, Fig. 1 bar graph: Relative
lumen area; for lower power views of larger fields see Fig. S1,
Supporting Information). Interestingly, the numbers of ECs per unit
area in cross-section was indistinguishable among DN calpain-I,
WT calpain-I, and empty-vector groups (Fig. 1 bar graph: ‘‘EC
density’’),indicatingthatexpressionofDNcalpain-IorWTcalpain-
I had no influence on EC number. Consistent with these
observations, co-culture of the various retroviral packaging cells
withthe VEGF-expressingSK-MEL-2cells in the same proportions
employed in vivo had no effect on VEGF production (see Methods),
as expected because VEGF expression inthissystem is constitutively
driven by a CMV promoter. Thus, the marked differences in lumen
formation among the different experimental groups can best be
explained by differences in blood vessel formation rather than
differences in EC density or VEGF expression.
Consistent withtheCD31-staininganalyses,microscopicanalyses
of the vasculature in whole mounts revealed that prominent
neovessel sprouts in the VEGF + DN calpain-I group were well
integrated and perfused by Evans blue dye, whereas neovessel
sprouts in the VEGF + empty vector group were poorly integrated,
exhibited blind ends, and were incompletely perfused (Fig. 1 Evans
Blue Dye).Insharp contrast,neovesselsintheVEGF +WTcalpain-
I group were virtually absent indicating total disruption of
angiogenesis by WT calpain-I. Quantification of perfused neovessel
density from gross images taken at dissection indicated that DN
calpain-Iincreased neovascularization 60%relative toempty-vector
controls; whereas, WT calpain-I inhibited neovascularization by
.80% (Fig. 1 bar graph: ‘‘Relative neovascularization’’). Perfusion
with lysine-fixable 70 kD Texas-red dextran and confocal micros-
copy confirmed the architectural distinctions observed with Evans
blue perfusion (Supporting Information, Fig. S1).
To analyze further the improvement in angiogenesis attributable
to DN calpain-I, we prepared vascular casts with Microfil perfusion
(Fig. 1, Vascular Cast with Microfil). Two parameters were
quantified: numbers of neovessels with blind ends and neovessel
integration with neighboring neovessels as measured by counting
closed vascular loops (polygons) [18]. These quantitative analyses
indicated that, relative to empty-vector, DN calpain-I reduced blind
ends .50% and increased the number of closed vascular polygons
.100%, thus indicating substantial improvement in vascular
integration (Fig. 1 bar graphs: ‘‘Polygons’’ and ‘‘Blind ends’’).
DN Calpain-I Supports Integration of Vascular Networks
During Capillary Morphogenesis In Vitro
To investigate cellular mechanisms through which calpain
controls neovessel formation and integration, we prepared cultured
human dermal microvascular ECs (MVECs) transduced with DN
calpain-I, WT calpain-I, and empty vector. Cells were cultured in
the continuous presence of VEGF to imitate conditions in vivo.A s
expected, MVECs transduced with DN calpain-I exhibited a
moderate but significant decrease (,35%) in calpain activity,
relative to controls, as measured with a fluorescent calpain substrate
assay (Fig. 2A, see Methods). Conversely, MVECs transduced with
WT calpain-I exhibited a moderate but significant increase in
activity (Fig. 2A). Next, these MVEC populations were stimulated
with three-dimensional collagen-I matrices, thereby inducing
assembly of vascular cord-like structures that are the precursors to
tubes with lumens [19,20]. This dynamic process closely resembles
formation of blood vessels in vivo [21,22]. Consistent with the in vivo
experiments described above, transduction of dermal MVECs with
retrovirus carrying DN calpain-I enhanced the inter-connectivity of
vascular cords in vitro (Fig. 2B, C). DN calpain-I increased cord
length, reduced blind ends, and increased formation of closed
polygon networks relative to empty-vector controls (Fig. 2B, C).
Conversely, transduction with retrovirus carrying WT calpain-I
reduced cord length, increased the number of blind ends, and
reduced formation of closed polygon networks (Figs. 2B, C).
Importantly, these findings established direct parallels with our
observations in vivo (Fig. 1), thereby confirming the value of this in
vitro assay for further investigations on mechanism.
DN Calpain-I Supports Vascular Cord Integration by
Improving Cytoskeletal Dynamics
Cytoskeletal analyses indicated that MVECs transduced with
either DN calpain-I or treated with calpastatin peptide, - a cell
Calpain and VEGF Angiogenesis
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active region of the natural calpain inhibitor calpastatin [23],
exhibited a robust microtubule cytoskeleton relative to controls
(Fig. 3A); quantification of microtubule length indicated a highly
significant increase of nearly 100% (Fig. 3B). In contrast, cells
transduced with WT calpain-I exhibited a significantly diminished
microtubule cytoskeleton (Fig. 3A, B). These observations
suggested the possibility that calpain activity regulates integration
of MVEC networks through microtubule stability. To test this
hypothesis, we performed capillary morphogenesis assays in vitro
with taxol (15 mM), - a microtubule-stabilizing agent, or
nocodazole (15 mM), - an inhibitor of microtubule polymerization.
Cords were allowed to form for 3 hours before taxol or nocodazole
were added, and cord formation was then allowed to proceed for
Figure 1. DN calpain-I improves VEGF neovessel lumen formation and integration in vivo. Transfected SK-MEL2 cells engineered to
express VEGF165 were mixed with retroviral packaging cells expressing retroviruses encoding either dominant-negative (DN) calpain-I, wild-type (WT)
calpain-I or control retrovirus (Empty Vector), as indicated, and injected together with Matrigel into the sub-dermal space as described in Materials
and Methods. After 8 days, the structure and function of the angiogenic response elicited in the overlying dermis was investigated. Animals were
harvested following 10 min perfusion with the indicated tracer and tissue sections were analyzed by immunohistochemistry. CD31 Stain: Staining of
ECs in cross section with CD31 antibody (brown color) illustrates that DN calpain-I improved lumen formation (red arrowheads) relative to Empty
Vector control, whereas WT calpain-I almost completely abolished lumen formation. Scale bar =25 microns. M = Matrigel, V = region of
neovascularization, S = skeletal muscle. Evans blue dye: Gross images of the vasculature in the dermis overlying the Matrigel implants (scale bar
=500 microns) show that DN calpain-I improved blood vessel integration and tracer perfusion (Note: all perfused blood vessels appear blue) and
reduced blind ends (white arrows) relative to Empty Vector control (Note: numerous red-tipped vessels indicating sprouts that have not been
perfused with Evans Blue tracer), whereas WT calpain-I blocked formation of new blood vessels. Vascular Cast with Microfil: Following perfusion of the
entire vasculature with Microfil, blind ends (red arrows) were found to be numerous in the Empty Vector control but vessel inter-connectivity was
substantially improved by transduction with DN calpain-I. Scale bar =450 microns. Bar graphs present quantification of relative lumen area from
CD31-stained sections; n$18 for each group, p,0.01 for DN calpain-I vs. empty vector and WT calpain-I vs. empty vector; ECs (per 0.01 mm
2) from
CD31-stained sections; n$18 for each group; relative neovascularization (from gross images); n$18 for each group; p,0.01 for DN calpain-I vs. empty
vector and WT calpain-I vs. empty vector; and quantification of polygons (closed vascular loops) (p,0.02) and blind ends (p,0.02) from vascular casts
with Microfil; $10 for each group. Values reported for polygons and blind ends correspond to a sample area of 12 mm
2.
doi:10.1371/journal.pone.0013612.g001
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microtubule stability for integration of MVEC capillary networks,
stabilization of microtubules with taxol markedly improved cord
length and reduced blind ends relative to controls (Fig. 3C, D).
Conversely, destabilization microtubules with nocodazole reduced
cord length and increased blind ends (Fig. 3C, D). Accordingly,
taxol-stabilization of microtubules improved vascular network
integration in vitro similarly to DN calpain-I (Fig. 2), whereas
nocodazole-destabilization of microtubules reduced network
integration similarly to WT calpain-I (Fig. 2). Therefore, our
observations that calpain inhibition enhances microtubules, and
that microtubule stability is important for the integration of
vascular networks are all consistent with the hypothesis that
calpain regulates integration of vascular networks through the
microtubule cytoskeleton.
Calpains act through cleavage of numerous intracellular
substrates, and many of these substrates regulate the cytoskeleton
and cell adhesion [6]. Therefore, we searched for protein targets in
MVECs, cultured in the presence of VEGF, that are regulated by
DN calpain-I, WT calpain-I, or calpastatin peptide. At the protein
level, in .7 separate experiments, we did not detect significant
regulation of the focal adhesion proteins paxillin, talin, vinculin, or
the cytoskeletal proteins vimentin and a-tubulin, - all of which can
be cleaved by calpains [6,24] (Supporting Information, Fig. S2).
However, we consistently observed decreased quantity of the
microtubule-stabilizing protein tau in MVECs transduced with
WT calpain-I, and increased tau in cells transduced with DN
calpain-I and in cells treated with calpastatin peptide (Fig. 3E, F).
Tau cleavage by calpain is well documented [6]; and tau is
important for microtubule stability [25,26], Therefore, these data
support the hypothesis that inhibition of calpain supports
integration of vascular cord networks by increasing tau and,
consequently, increasing microtubule stability.
Finally, and consistent with previous findings that calpain
suppresses Rho activity by cleaving RhoA to generate a dominant-
negative form [27], we found that calpain-inhibitory calpastatin
peptide modestly but significantly increased Rho activity in dermal
MVECs (Supporting Information, Fig. S3A). Comparably modest
increases in RhoA activity have been shown previously to increase
actin stress fibers in dermal MVECs [15]. Moreover, consistent
with increased Rho activity, calpastatin peptide and DN calpain-I
each increased actin stress fibers relative to controls in confluent
quiescent cultures of dermal MVECs whereas WT calpain-I nearly
abolished stress fibers and (Supporting Information, Fig. S3B).
Similarly, in MVECs undergoing cord formation in response to
stimulation with collagen I, both calpastatin peptide and DN
calpain-I markedly increased actin cable length (Supporting
Information Fig. S3C, D). Collectively, these observations raise
the possibility that regulation of actin cytoskeletal dynamics, in
addition to regulation of microtubule stability, is also important to
the mechanism by which calpain regulates capillary morphogen-
esis and network integration.
Figure 2. Calpain activity regulates integration of vascular networks during capillary morphogenesis in vitro. (A) Quantification of
relative calpain activity, as determined with a fluorescent calpain substrate assay (see Methods) in MVECs transduced with DN calpain-I, empty vector,
or WT calpain-1 (n.17 and p#0.01 for all comparisons). (B) Equal numbers of transduced dermal MVECs (+20 ng/ml VEGF) were overlaid with three-
dimensional collagen-I to induce assembly of vascular cords. Relative to empty vector control, transduction with DN calpain-I enhanced inter-
connectivity of vascular cords. In contrast, WT calpain-I increased blind ends (white arrows) and diminished cord inter-connectivity. Bar =100 mm. (B)
Quantification of EC density and cord organization; n$17 for each group; measured parameters correspond to actual areas of 0.4 mm
2. Cord length:
p,0.001 for DN calpain-I vs. empty vector and WT calpain-I vs. empty vector. Blind ends: p,0.002 for DN calpain-I vs. empty vector and WT calpain-I
vs. empty vector. Polygons (closed vascular loops): p,0.001 for DN calpain-I vs. empty vector and WT calpain-I vs. empty vector.
doi:10.1371/journal.pone.0013612.g002
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Activity with Calpain Inhibitor-I Supports Integration of
Vascular Networks In Vitro and Improves Lumen
Formation and Integration of VEGF Neovessels In Vivo
Consistent with previous reports that VEGF induces calpain
activity in MVECs from lung and skin [13,14], we found that
VEGF, at the concentration routinely employed in all of our in vitro
experiments (20 ng/ml), induced calpain activity .50% (Fig. 4A).
Calpastatin peptide (200 nM) and another calpain inhibitor,
calpain inhibitor-I, also known as ALLN (200 nM), each reduced
calpain activity in VEGF-stimulated cells to levels present in the
absence of VEGF stimulation. Moreover, 200 nM ALLN, which
suppressed calpain activity to baseline identically with 200 nM
calpastatin peptide (Fig. 4A), markedly improved integration of
vascular cords as measured by reduction in blind ends and
increased network connectivity (Fig. 4B, C). However, higher
doses of ALLN ($2.0 mM) did not improve integration of cords,
but rather these doses were inhibitory and caused cell rounding
(not shown). Notably, these higher doses of ALLN ($2 mM)
severely inhibited calpain activity in comparison with 200 nM
ALLN (Fig. 4A), underscoring the importance of moderate calpain
inhibition to achieve the desired outcome. To summarize, these
experiments indicate that: (1) VEGF induction of calpain activity is
likely responsible for impaired integration of vascular cords, and
(2) that normalization of calpain activity to baseline levels with
calpain inhibitor-I, improves integration of vascular cords
comparably to DN calpain-I (Fig. 2). Moreover, these findings
suggested that systemic administration of this inhibitor might
similarly improve neovascularization in vivo. To test this possibility,
we employed the same VEGF-driven angiogenesis model
described above but without retroviral packaging cells. Instead
animals were treated with calpain inhibitor-I (ALLN), which has
been used extensively in animal models but for other applications
[28,29,30,31]. In initial pilot experiments, calpain inhibitor-I was
administered daily (5, 10, 15, and 20 mg/kg, i.p.) beginning on
day two following implantation of the VEGF-transfectants. No
adverse effects on animal health were observed with any of these
doses. As determined grossly in these pilot experiments at day 8,
the 20 mg/kg dose clearly inhibited angiogenesis. In contrast, the
10 mg/kg dose did not inhibit neovascularization but rather
improved the integration of neovessels. Therefore, more extensive
experiments and analyses were performed with the 10 mg/kg
dose. As quantified grossly and in cross-section (Figure 4 D, E),
10 mg/kg daily calpain inhibitor-I markedly reduced blind ends
and increased vessel lumens similarly to DN calpain-I. These
improvements in neovascular architecture were accomplished
without any detectable effect on EC density (Figure 4E), indicating
that daily administration of 10 mg/kg calpain inhibitor-I did not
affect EC number. Similar to DN calpain-I, calpain inhibitor-I
(200 nM, ,1 x IC50) had no effect on production of VEGF by
SK-MEL2 cells (the source of VEGF expression) (see Methods),
consistent with the fact that VEGF expression was driven
constitutively by a CMV promoter. Thus, the cumulative evidence
indicates that improvement in neovascular architecture by calpain
inhibitor-I is best explained by improvement in capillary
morphogenesis rather than by differences in EC density or VEGF
expression.
Discussion
Although defects in neovascular architecture associated with
pathological angiogenesis are well recognized (reviewed [2,3]),
mechanistic explanations have been lacking. Experiments de-
scribed here identify VEGF-induction of calpain activity as an
important and previously unrecognized mechanism responsible for
failed integration of neovascular networks. As demonstrated here
with a mouse skin model of VEGF-driven angiogenesis, expression
of an established DN mutant of calpain-I reduced vascular blind
ends and markedly improved network integration and vascular
perfusion. Conversely, over-expression of WT calpain-I abolished
integration of neovascular networks. Importantly, daily adminis-
tration of calpain inhibitor-I, at 10 mg/kg, markedly improved
neovascular network integration and perfusion in vivo similarly to
DN calpain-I.
Calpains are a complex family, and multiple isoforms may be
involved in regulating integration of neovascular networks [6].
The most likely candidates are calpain-I and/or calpain-II which
are both are expressed by ECs [32]. Calpain-I is activated by
micro-molar calcium whereas calpain-II is activated by milli-molar
calcium and by the ERK pathway [6,33]. VEGF induces calcium
uptake and also releases free calcium from intracellular stores
[34,35] suggesting a mechanism for activating calpain-I. VEGF
also activates the ERK pathway [36] and activates calpain-II
[13,14]. Our experiments with WT calpain-I establish that over-
expression of calpain-I has strong negative consequences for
VEGF neovascular network integration both in vivo and in vitro.
Conversely, DN calpain-I and calpain inhibitor-I at the appropri-
ate dose strongly improve network integration. Although both DN
calpain-I and calpain inhibitor-I suppressed calpain activity in
MVECs as measured with a calpain fluorescent substrate assay,
our experiments do not identify which of the various calpain
isoforms were inhibited. Nonetheless, and regardless of which
calpain isoforms are involved, our studies establish a functional
connection between over-exuberant calpain activity and the failed
integration of neovascular networks during VEGF-driven angio-
genesis.
Figure 3. DN calpain-1 supports integration of vascular cord networks by enhancing the microtubule cytoskeleton. (A) MVECs
transduced with DN calpain-I or calpastatin peptide (200 nM) exhibited a robust microtubule cytoskeleton relative to Empty Vector controls. In
contrast, cells transduced with WT calpain-I exhibited a markedly diminished microtubule cytoskeleton. Microtubules were stained with a-tubulin
antibody; bar =25 mm. (B) Quantification of mean microtubule lengths (n.20 cells; p,0.001 for DN calpain-I vs. empty vector; p,0.05 for WT
calpain-I vs. empty vector; p,0.001 for calpastatin peptide vs. vehicle control). (C) Equal numbers of MVECs were stimulated with collagen-I to
undergo capillary morphogenesis (as in Figure 2). Treatment with the microtubule-stabilizing agent taxol (15 mM) during the final hour of cord
formation, i.e. three hours after the initiation of capillary morphogenesis (see Methods), improved cord formation and reduced blind ends whereas
incubation with the microtubule-destabilizing agent nocodazole (15 mM) impaired cord formation and increased blind ends (white arrows). Cords
were stained for F-actin with phalloidin; bar =50 mm. (D) Quantification of cord organization; n$17; measured parameters correspond to actual areas
of 0.4 mm
2. Cord length: taxol vs. control p,0.001; nocodazole vs. control p,0.001. Blind ends: taxol vs. control p,0.002; nocodazole vs. control
p,0.003. Polygons (closed vascular loops): taxol vs. control p,0.001; nocodazole vs. control p,0.001. (E) As determined with immunoblotting, the
microtubule-stabilizing protein tau was increased in MVECs treated with calpastatin peptide or transduced with DN calpain-I, and decreased in MVECs
transduced with WT calpain-I relative to empty vector (Ctrl). Total Erk1/Erk2 served as loading controls (see Methods). (F) Quantification of tau protein
from blots stained with anti-tau antibody; n$5. Calpastatin peptide vs. control: p,0.03. DN calpain-I vs. empty vector control: p,0.03. WT calpain-I
vs. empty vector control: p,0.05.
doi:10.1371/journal.pone.0013612.g003
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calpain activity as a therapeutic strategy to reduce key architec-
tural defects associated with VEGF-driven angiogenesis. Blind
ends and poor network integration limit vascular perfusion and
seriously reduce the utility of VEGF as a therapeutic agent for
tissue revascularization [2]. Abnormal neovessels also contribute to
the pathology of disease. For example, in ischemic retinopathies,
abnormal neovascularization largely driven by VEGF damages
retina and can ultimately lead to blindness [37]. Our findings
illustrate that moderate calpain inhibition is a potentially
important strategy for rectifying defects in pathological neovessels
and also for achieving more functional therapeutic angiogenesis
with VEGF. However, it is important to emphasize that
appropriate inhibition of calpain is essential for the desired
Figure 4. VEGF increases calpain activity in MVECs, and calpain inhibitor-I improves VEGF angiogenesis. (A) MVECs, cultured in the
absence of VEGF, were incubated with fluorescent calpain substrate (see Methods) and stimulated with 20 ng/ml VEGF for 15 min; n$10; control vs.
VEGF (p,0.001), VEGF vs. VEGF plus 200 nM calpastatin peptide (p,0.002), VEGF vs. VEGF plus 200 nM ALLN (p,0.002). (B) VEGF-stimulated MVECs
undergoing capillary morphogenesis in 3D collagen. Reduction of calpain activity to normal baseline levels with 200 nM calpain inhibitor-I reduced
blind ends (white arrows) and markedly improved integration of cord networks. Bar =50 mm. (C) Quantification of cord assays shown in (B); n$15.
Measured parameters correspond to values for samples areas of 0.4 mm
2. Calpain inhibitor-I at the 200 nM dose had no effect on EC density but
strongly improved vascular network integration, as indicated by .100% increase in average cord length (p,0.003), .50% reduction in blind ends
(p,0.001), and nearly 50% increase in polygons, i.e. closed networks (p,0.005). (D) Daily systemic administration of calpain inhibitor-I (10 mg/kg)
improves integration and perfusion of new blood vessels. Skin angiogenesis was provoked by VEGF as in Figure 1 but without retroviral packaging
cells. Instead animals were treated daily, beginning on day 2, with 10 mg/kg calpain inhibitor-I and harvested on day 8. Evans Blue Dye: images of
dermis overlying the Matrigel implants (scale bar =250 microns) following perfusion with dye for 10 min, illustrating that calpain inhibitor-I improved
blood vessel integration and perfusion (blue color) and reduced blind ends (arrows) relative to vehicle control. CD31 Staining: ECs in cross section
stained with CD31 antibody (brown color) illustrating that calpain inhibitor-I improves lumen formation (arrows) relative to control. Scale bar =30
microns. S = smooth muscle, V = region of neovascularization, M = Matrigel. (E) Quantification of new blood vessel density, closed vascular
networks (polygons), and blind ends from gross images, and EC density and relative lumen area in cross-section from paraffin sections stained with
CD31 antibody; n$17. Gross vessel density (p,0.01), polygons (p,0.03), blind ends (p,0.01), relative lumen area (p,0.01). Numbers of polygons
and blind ends correspond to sample areas of 10 mm
2.
doi:10.1371/journal.pone.0013612.g004
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angiogenesis with 20 mg/kg daily calpain inhibitor-I, whereas
10 mg/kg daily improved rather than inhibited angiogenesis.
In particular, our in vitro experiments established that partial
inhibition of calpain activity in MVECs, - specifically by reducing
activity to the baseline level present in the absence of VEGF-
stimulation, provides marked improvement in vascular cord
integration, whereas higher doses of calpain inhibitor impaired
cord formation and caused cell rounding. In a previous report,
plasmid transfection of aortic ECs with DN calpain-I caused cell
rounding [8]; but we did not observe cell rounding in dermal
MVECs transduced by retrovirus with DN calpain-I, probably
because the level of DN calpain-I expression achieved and
consequently the extent of calpain inhibition achieved was more
modest. Nonetheless, we did observe cell rounding in dermal
MVECs with calpain inhibitor-I, at doses that inhibited calpain
activity more severely than retroviral transduction with DN
calpain-I. Also, others have reported previously that calpain
inhibition can suppress angiogenesis in vivo [13] and that calpain
inhibition can block capillary morphogenesis in vitro [14]. Our
findings do not challenge this view; rather they illustrate that more
modest calpain inhibition can actually improve network integra-
tion. Indeed, suppression of angiogenesis with relatively high doses
of calpain inhibitors is not surprising given the importance of
calpain activity for basic cellular functions such as adhesion and
migration [7,8,38,39]. However, our study illustrates the unantic-
ipated finding that appropriately modest inhibition of calpain
activity improves rather than blocks VEGF-driven angiogenesis.
It is also important to emphasize that our experimental findings
pertain to VEGF-driven pathological angiogenesis in a mouse
model without any disease-related complications. Co-morbid
factors such as diabetes and hyper-cholesterolemia cause endo-
thelial dysfunction that seriously hinders neovascularization in
response to pro-angiogenic therapy [40,41]. Thus, in the future, it
will be important to determine whether the calpain inhibitor
strategy described here also can facilitate VEGF pro-angiogenesis
therapy in the presence of endothelial dysfunction due to
underlying disease or if such dysfunction must first be addressed
with additional, unrelated intervention.
Mechanistically, our in vitro experiments indicate that hyper-
activation of calpain impairs neovascular network integration and
causes blind ends by destabilizing the microtubule cytoskeleton,
thereby impairing normal capillary morphogenesis. In particular,
our data indicate that reduction of the microtubule-stabilizing
protein tau, a well-recognized calpain substrate, is likely
responsible for failed neovascular inter-connectivity. Consistent
with a critical requirement of microtubules for proper capillary
morphogenesis and network integration, we found that microtu-
bule destabilization with nocodazole strongly inhibited integration
of cord networks; and these findings are consistent with previous
work demonstrating that microtubule de-polymerizing agents
induce collapse of new blood vessels in vivo and vascular structures
in vitro [42]. Interestingly, calpain also has been implicated in the
collapse of neurite extensions by destabilizing microtubules [43],
suggesting a fundamental parallel with findings reported here.
Similarly, calpain activation in neurite filipodia slows neurite
outgrowth and promotes repulsive growth cone turning [44].
It is important to distinguish microtubule stabilization by tau
protein, which is elevated by calpain inhibition, from artificial
microtubule stabilization mediated by taxol. Tau-mediated
stabilization of microtubules is sensitive to normal regulation by
phosphorylation and is therefore dynamic [45,46]. In contrast,
taxol (paclitaxel) hyper-stabilizes microtubules, thereby forming a
static tubulin/paclitaxel complex that suppresses the normal
dynamic behavior of microtubules [47,48,49]. Consistent with
reduced microtubule dynamics, taxol has been shown to inhibit
angiogenesis [50,51,52]; and although we found that taxol
improved vascular cord inter-connectivity in vitro when adminis-
tered after cords had begun to form, taxol blocked cord formation
if administered prior to the onset of capillary morphogenesis. In
contrast, we found that appropriate inhibition of calpain activity
improved inter-connectivity of cords even when calpain inhibitors
were administered prior to the initiation of capillary morphogen-
esis.
Other than the microtubule-stabilizing protein tau, we observed
no detectable effects of calpain on other known calpain substrates
including paxillin, talin, vinculin, vimentin and a-tubulin, -
indicating a selectivity for tau in MVECs. However, we did
observe a modest but significant reduction in Rho activity,
consistent with previous work demonstrating that calpain
generates a dominant-negative form of RhoA in ECs [27]. This
finding is also consistent with our observations that calpain activity
impairs the length and organization of actin stress fibers in
MVECs that are regulated by RhoA [15]. In addition, RhoA-
mediated actin dynamics are essential for aligning MVECs into
capillary cords in vitro and also for organizing MVECs into new
blood vessels in vivo [15]. Thus, calpain-mediated suppression of
RhoA activity and actin stress fibers are also likely important to the
mechanism by which calpain activity impairs the quality of VEGF-
driven angiogenesis. Accordingly, our findings suggest the more
general hypothesis that impaired regulation of the EC cytoskeleton
is responsible for neovascular defects [3]. Because multiple
signaling pathways regulate the cytoskeleton [53,54], there may
prove to be multiple cytoskeletal-targeting strategies, in addition to
calpain, for rectifying pathological angiogenesis [3]. Moreover,
multiple targeting strategies used in combination may be required
to achieve more complete rectification of pathological neovessels.
Finally, because calpain activity regulates neovessel integration
during angiogenesis, it seems likely that calpain activity relates to
fundamental mechanisms by which sprouting EC tip cells [55] link
up with distal sprouting EC tip cells to establish a new contiguous
blood vessel. To establish connections with other sprouting ECs at
a distance, sprouting tip cells are believed to establish guidance
pathways within the extracellular matrix through tensional forces,
i.e. by creating a ‘‘matrical track’’ [21] or ‘‘matrix guidance
pathway’’ [56]. A tensional signal is transmitted through the
extracellular matrix by tractional forces exerted by extending tip
cells, and the success of this process very likely depends on the
dynamic stability of tip cell extensions. Although further study is
required to address the involvement of calpain activity directly in
this process, it is tempting to speculate that VEGF-activation of
calpain activity impairs the stability of tip cell extensions and
thereby impairs the ability of these extensions to establish the
tensional forces required for linking-up with other sprouting tip
cells from distal vessels. This possibility is entirely consistent with
the role of calpain activity in tail retraction, i.e. in promoting rear
end detachment in migrating cells [10] and in promoting neurite
retraction [43], as discussed above.
In summary, VEGF activates calpain activity in MVECs
resulting in over-exuberant calpain activity that inhibits the
integration of neovascular networks, thereby causing formation
of vascular blind ends. Moreover, at the cellular level, VEGF-
induced calpain activity impairs neovessel integration by destabi-
lizing the microtubule cytoskeleton. Collectively, these experi-
ments identify hyper-activation of calpain as responsible for a
previously unexplained neovascular defect commonly associated
with pathological angiogenesis, and they provide new understand-
ing as to why VEGF induces abnormal neovascularization. They
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regulating blood vessel formation and integration. Finally, these
studies identify appropriately modest inhibition of calpain as a
previously unrecognized method for improving integration and
perfusion of VEGF-induced neovessels. Accordingly, this rational
pharmacological strategy offers promise for improving vascular
outcomes in clinical settings wherein rectifying defects in
pathological neovessels or improving therapeutic angiogenesis is
the desired goal [2].
Materials and Methods
Reagents
Purified recombinant human VEGF165, expressed in Sf21 cells,
was obtained from the NCI Preclinical Repository, Biological
Resources Branch, Frederick, MD. TAU-5, paxillin, talin, ERK1/
2 (K-23), and RhoA antibodies were from Chemicon international
(Temecula, CA). Vinculin, vimentin, and a ˜-tubulin (Clone DM
1A) antibodies, taxol and nocodazole were from Sigma-Aldrich
(St. Louis, MO). ECL Western Blotting Substrate kit was from
Pierce (Rockford, IL). Texas-Red secondary antibody for micro-
tubule staining was from Jackson Immunoresearch (West Grove,
PA). CD31 (PECAM-1) antibody was from BD Biosciences
Pharmingen (San Diego, CA). DAB substrate Kit was from
Zymed Laboratory Inc. (Carlsbad, CA). Matrigel and collagen-1
were from BD Biosciences (Bedford, MA). Oregon Green-
conjugated phalloidin was from Invitrogen. Calpain inhibitor-I
(ALLN) and calpastatin peptide were from Calbiochem (Gibbs-
town, NJ). Lysine-fixable Texas-red dextran (MW 70 kD) for
perfusion studies was from Invitrogen (Carlsbad, CA).
Preparation of Packaging Cells Expressing Retroviruses
Encoding DN Calpain-I and WT Calpain-I
Previously validated DN calpain-I and WT calpain-I cDNAs [8]
were subcloned into retrovirus vector pLNCX2 (Clontech, Palo
Alto, CA) through HindIII/NotI sites. Clones were verified by
sequencing. PT67 retroviral packaging cells (Clontech, Palo Alto,
CA), which express the 10A1 viral envelope for production of
amphotropic virus, were transfected with pLNCX2 vector
containing DN calpain-I, WT calpain-I, or vector without insert
(empty vector). Transfectants were cloned, and clones expressing
retrovirus at 1610
5 c.f.u./ml were selected for subsequent
experiments.
Angiogenesis in Mouse Skin, Retroviral Transduction and
Drug Administration In Vivo, and Analyses of Vascular
Parameters
Neovascularization was investigated in vivo according to a
previously established method that includes both VEGF165-
transfected SK-MEL2 cells and retroviral packaging cells, thereby
providing a constant source of VEGF and retrovirus [15,16].
Seven week old female athymic nude mice were injected
subcutaneously on right and left flanks with 0.3 ml of 9 mg/ml
Matrigel (BD Biosciences) containing 1610
6 VEGF165-SK-MEL2
cells together with 1610
6 retroviral packaging cells, as indicated.
Untransfected parental SK-MEL2 cells do not provoke angiogen-
esis detectably, and therefore the VEGF165-SK-MEL2 transfec-
tants employed here allow for specific investigation of VEGF-
driven angiogenesis [57]. At times indicated, the animals were
euthanized, dissected, and photographed. In addition, to analyze
perfusion of new blood vessels, representative animals from each
group received tail vein injections of 0.2 ml of 0.5% (w/v) Evan’s
Blue dye or 70 kD Texas-red dextran (25 mg/ml) in sterile saline.
Gross images of perfused vessels were obtained using a Wild M400
Stereomicroscope and SPOT Insight digital camera. For whole
mount immunofluorescence analysis of Texas-red dextran tracer-
filled vasculature, skin samples were fixed in 4% paraformalde-
hyde for 4 hr, dehydrated with a graded series of ethanol solutions
(50–100%) and cleared with methyl salicylate, mounted in
immersion oil, and viewed with a Bio-Rad MRC-1024 Confocal
Microscope equipped with an Argon-Krypton Laser. Four-six
fields per sample were visualized using x10 objective. For
histology, Matrigel implants together with associated skin were
fixed for 1 hour in 10% buffered formalin and embedded in
paraffin. Immuno-histochemical staining of ECs with CD31
antibody was performed as described [16]. Neovascular density
and lumen area were traced through freehand selections on digital
images and measured with NIH ImageJ software. EC density was
measured through freehand point selections with NIH ImageJ
software.
Vascular architecture was also analyzed with Microfil perfusion.
The entire vascular tree of the mouse was filled with Microfil MV-
122 (Flow Tech; Carver, MA) [58]. The Microfil was allowed to
polymerize for 24 h at 4uC. Specimens of flank skin were cleared
by dehydration in a graded series of glycerin solutions (50–100%)
and photographed using a Wild M400 Stereomicroscope and
SPOT Insight digital camera. Blind ends and polygons (closed
vascular loops) were quantified through freehand point selections
with NIH ImageJ software.
Finally, for experiments with calpain inhibitor-I (ALLN),
angiogenesis assays were performed as above but without
retroviral packaging cells. ALLN was administered daily i.p. at
10 mg/kg in saline vehicle unless indicated otherwise.
MVEC Isolation, Cell Culture, and Retroviral Transduction
of MVECs
Human dermal MVECs were isolated from neonatal foreskins
[59] and cultured [16] in the continuous presence of 20 ng/ml
VEGF165. All experiments were performed with cells at the fourth
to seventh passage. MVECs at passage 5 or less were transduced
with retroviruses according to a previously established, efficient
method [60]. The transduction procedure was repeated three
times on consecutive days before subjecting cells to selection with
300 micrograms/ml G418. This method yields100% transduction
as indicated with GFP vectors [15,16]. Cells were used within one
week after selection for experiments.
Capillary Morphogenesis Assays with MVECs In Vitro;
Quantification of Parameters
Capillary morphogenesis assays were performed by ‘‘overlay-
ing’’ and ‘‘sandwiching’’ confluent cell monolayers with rat tail
collagen-I (BD Biosciences [15,16]. The sandwich-type assay was
performed in 12-well plates with 1.0 mg/ml collagen-I in full
medium. Where applicable, calpain inhibitors were added for
overnight incubation, prior to adding the upper layer of collagen-I.
Capillary morphogenesis was allowed to proceed for 16 h; the
assay plates were fixed with 10% formalin for one hour and
stained for F-actin with fluorescent Oregon Green-conjugated
phalloidin (Invitrogen, final concentration 0.5 units/ml) and
subsequently photographed. For the ‘‘overlay’’ assay, calpain
inhibitors were added and incubated with cells in 24-well plates
overnight. The next day, each well was overlaid with 300
microliters of collagen-I at a concentration of 0.5 mg/ml in
serum-free medium together with inhibitors as indicated. Capillary
morphogenesis was allowed to proceed for 4 h. For capillary
morphogenesis assays involving taxol or nocodazole, cords first
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where indicated, for the final hour of the assay. In all cases, cells
were fixed in 10% formalin for 10 minutes, permeabilized for one
minute with 0.02% Triton-X100 in PBS and stained for F-actin (as
above). Cells were photographed with a Nikon inverted fluorescent
microscope and digital camera. In all cases, cord length, blind
ends, and polygons were quantified using NIH ImageJ software.
Cord length was traced and measured through freehand line
selections; cords were traced from one edge of the microscopic
frame to another, following the least circuitous route. Moreover,
cord length was traced and determined independently of
intersecting cords. Blind ends and polygons were determined with
point selections. Measured parameters correspond to actual areas
of 0.4 mm
2. Statistical analyses were performed as described
below.
Analyses of Cytoskeletal Proteins, Rho Activity, and VEGF
Expression
MVECs transduced with DN or WT calpain-I or empty vector
were grown to confluence in full medium. Where indicated,
calpastatin peptide (200 nM) was added 24 hours before harvest.
MVECs were harvested in lysis buffer (20 mM Tris-HCl, 150 mM
NaCl, 10% Glycerol, 1% Nonidet P-40, 3 mM MgCl2,1m M
EDTA, 1 mM EGTA, 5 mM Na3VO4, 150 mM sodium pyro-
phosphate, plus a cocktail of proteases inhibitors containing 4-(2-
aminoethyl)benzenesulfonyl fluoride (AEBSF), pepstatin A, E-64,
bestatin, leupeptin, and aprotinin. Lysate (20 mg protein) was
subjected to electrophoresis with SDS PAGE on a 4–20% gradient
gel. Gels were electrophoretically transferred to PVDF Membrane
(BIO-RAD) and stained with antibodies (as indicated). Total
Erk1/Erk2 served as loading controls; we have found these
proteins to be particularly suitable and preferable as loading
controls because they are invariant in MVECs under a variety of
experimental conditions [61,62]. Protein bands were detected with
ECL Western blotting substrate. Active GTP-Rho (1610
7 ECs/
sample) was measured with an established ‘‘pull-down’’ assay
followed by immunoblotting [63]. Blots were stained with rabbit
polyclonal antibody to RhoA (#SC-179, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA). Active Rho was quantified with a digital
scanner. To assay for any effects of retroviral transduction or
calpain inhibitor-I on VEGF expression, VEGF165-SK-MEL2
cells were transduced with the various calpain retroviruses
(described above) or treated continuously with calpain inhibitor-I
(0.2 mM, 2.0 mM). Medium was harvested daily for 8 days, and
VEGF165 was concentrated with heparin-Sepharose chromatog-
raphy [64] followed by electrophoresis and immunoblotting with
VEGF-specific antibody [65] and quantification with a digital
scanner.
Calpain Fluorometric Assay
Calpain activity was measured in live dermal MVECs with an
established fluorescent calpain substrate 7-amino-4-chloromethyl-
coumarin, t-BOC-L-leucyl-L-methionine amide (CMAC, t-BOC-
Leu-Met; from Invitrogen) [66]; and calpain inhibitors, as
indicated, were used to establish specificity. Cells were incubated
with 20 mM for 15 min at 37 degrees C; cleavage product was
measured with a SpectraMax M5 fluorescent plate reader
(excitation/emission 351/430) with SoftMax Pro5 software
(Molecular Devices, Sunnyvale CA).
Statistical Analyses
All data are presented as mean 6 S.E.M. Statistical analyses
were performed with InStat 3 software for Macintosh, employing
the two-tail Mann-Whitney test and assuming unequal variances
between the two groups under comparison. In all cases, an
individual experimental group was compared with the appropriate
control group; and calculated p-values are based on direct
comparisons between the two groups, unless indicated otherwise.
Supporting Information
Figure S1 Angio-architecture of VEGF neovessels as viewed in
whole mounts and in cross sections. Tx-Red dextran: Whole
mount fluorescent images of the dermal vasculature perfused with
TX-Red dextran confirm enhancement in vessel interconnectivity
by DN capain-1 and disruption of network integration by WT
calpain-I in comparison with Empty Vector control (scale bar
=100 mm). CD31 Stain: Staining of ECs in cross section with
CD31 antibody (brown color) illustrates that DN calpain-I
improved lumen formation (red arrowheads) relative to Empty
Vector control, whereas WT calpain-I almost completely abol-
ished lumen formation. Scale bar =50 mm. See Fig. 1 in the text
for higher power views of CD31 staining. S = skeletal muscle, V
= region of neovascularization, M = Matrigel.
Found at: doi:10.1371/journal.pone.0013612.s001 (9.70 MB TIF)
Figure S2 Survey of potential calpain substrates in dermal
MVECs. Unfractionated lysates from equal numbers of MVECs
transduced with DN calpain-I, WT calpain-I or empty vector
(Ctrl); and control cells treated with calpastatin peptide 24 h prior
to harvest were subjected to immuno-blotting and stained with
antibodies, as indicated. At the protein level, measurable changes
in levels of proteins paxillin, talin, vinculin, or the cytoskeletal
proteins vimentin and a-tubulin were not detected. Total Erk1/
Erk2 served as loading controls (see Methods).
Found at: doi:10.1371/journal.pone.0013612.s002 (2.86 MB TIF)
Figure S3 Calpain regulation of Rho activity and actin stress
fibers in dermal MVECs. (A) MVECs treated with calpastatin
peptide (200 nM, 24 h prior) exhibited modest but significant
increases in Rho activity, consistent with the increase in stress
fibers (p,0.05; n=7). (B) MVECs treated with calpastatin peptide
(200 nM, 24 h prior) or transduced with DN calpain-I exhibited
increased actin stress fibers relative to Empty Vector controls, as
determined with phalloidin staining. In contrast, cells transduced
with WT calpain-I exhibited no stress fibers with actin confined to
the cell periphery. Bar =25 mm. (C) Calpain regulation of the
actin cytoskeleton during formation of capillary cords. In all
panels, equal numbers of transduced MVECs were stimulated to
undergo capillary morphogenesis with collagen-I, and F-actin was
stained with phalloidin. Calpastatin peptide and DN calpain-I
improved organizational alignment of large actin cables (arrows)
and improved formation of capillary cords; in contrast, WT
calpain-I disrupted actin organization (arrows) and retarded
collagen-induced cord formation. Bar =25 mm. (D) Measured
lengths of adjoining actin cables in cords; n.19. DN calpain-I vs.
control (p,0.001), WT calpain-I vs. control (p,0.003).
Found at: doi:10.1371/journal.pone.0013612.s003 (5.92 MB TIF)
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